Home Cart Sign in  
Chemical Structure| 866028-26-4 Chemical Structure| 866028-26-4

Structure of INF39
CAS No.: 866028-26-4

Chemical Structure| 866028-26-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

INF39 is an irreversible NLRP3 inhibitor with IC50 value of ~100 μM for inhibiton of NLRP3 ATPase, which can inhibit IL-1β release, caspase activation and pyroptosis in THP-1 cells.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of INF39

CAS No. :866028-26-4
Formula : C12H13ClO2
M.W : 224.68
SMILES Code : O=C(OCC)C(CC1=CC=CC=C1Cl)=C
MDL No. :MFCD27930542
InChI Key :VTAOWWAFBSFWSG-UHFFFAOYSA-N
Pubchem ID :69150705

Safety of INF39

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical vein endothelial cells (HUVECs) 10 μM 48 hours Inhibited high glucose-induced NLRP3 inflammasome activation, significantly reducing the expression of NLRP3, ASC, caspase-1, IL-18, and IL-1β. Mediators Inflamm. 2019 Feb 19;2019:1082497
H9C2 cardiomyocytes 10 mmol/L To observe the effect of INF39 on NLRP3 pathway changes. Results showed that mRNA expression of SLC26A4, ASC, NLPR3, and caspase-1 significantly decreased after INF39 treatment. Sci Rep. 2025 Apr 11;15(1):12511
Rat cardiomyocytes H9C2 10mM After INF39 intervention, the cell surface area significantly decreased, and the expression of miR-26a-5p, ACS, NLRP3, and Caspase-1 was significantly downregulated. BMC Cardiovasc Disord. 2024 Jan 3;24(1):18
human annulus fibrosus cells 10 μM INF39 inhibits the activation of the NLRP3 inflammasome, thereby reducing pyroptosis in annulus fibrosus cells Acta Biochim Biophys Sin (Shanghai). 2022 Nov 25;54(11):1720 - 1730

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Severe acute pancreatitis (SAP) model Intraperitoneal injection 25 mg/kg or 50 mg/kg Single dose INF-39 reduced the severity of SAP and P-ALI in a dose-dependent manner. Biomed Res Int. 2018 Nov 28;2018:1294951
Sprague-Dawley rats DNBS-induced colitis Oral 25 mg/kg/day Once daily for 6 days To evaluate the anti-inflammatory effects of INF39 in DNBS-induced colitis. Results showed that INF39 significantly attenuated body weight loss, spleen weight increase, colon shortening, and levels of MPO, TNF, and IL-1β in colonic tissues. Front Pharmacol. 2018 Dec 3;9:1405
C57BL/6 mice DSS-induced acute colitis model Intraperitoneal injection 12.5 mg/kg Once daily for 7 days To study the effect of INF39 on DSS-induced acute colitis, results showed that INF39 enhanced the anti-inflammatory effects of Arctigenin Am J Transl Res. 2019 Jul 15;11(7):3992-4009

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.45mL

0.89mL

0.45mL

22.25mL

4.45mL

2.23mL

44.51mL

8.90mL

4.45mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories